BR112016013961A2 - angiotensina ii sozinha ou em combinação para o tratamento da hipotensão - Google Patents
angiotensina ii sozinha ou em combinação para o tratamento da hipotensãoInfo
- Publication number
- BR112016013961A2 BR112016013961A2 BR112016013961A BR112016013961A BR112016013961A2 BR 112016013961 A2 BR112016013961 A2 BR 112016013961A2 BR 112016013961 A BR112016013961 A BR 112016013961A BR 112016013961 A BR112016013961 A BR 112016013961A BR 112016013961 A2 BR112016013961 A2 BR 112016013961A2
- Authority
- BR
- Brazil
- Prior art keywords
- angiotensin
- mcg
- norepinephrine
- equivalent
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se, por exemplo, a um método que compreende a administração, a um indivíduo que tem um elevado choque de débito cardíaco e está sendo submetido a um tratamento com uma catecolamina a uma dose equivalente a pelo menos 0,2 mcg/kg/min de norepinefrina em que uma dose de angiotensina ii é eficaz para elevar a pressão sanguínea do indivíduo até uma pressão arterial média (map) de cerca de 65 mm de hg ou mais, e que é eficaz para reduzir a dose da catecolamina requerida para manter uma map de cerca de 65 mm de hg ao equivalente de cerca de 0,05 a 2,0 mcg/kg/min de norepinefrina ou menos, ou ao equivalente de cerca de 0,05 mcg/kg/min de norepinefrina ou menos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917576P | 2013-12-18 | 2013-12-18 | |
| US201461955706P | 2014-03-19 | 2014-03-19 | |
| PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016013961A2 true BR112016013961A2 (pt) | 2017-10-10 |
Family
ID=53367119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013961A BR112016013961A2 (pt) | 2013-12-18 | 2014-12-18 | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9220745B2 (pt) |
| EP (2) | EP2986308B1 (pt) |
| JP (3) | JP6824739B2 (pt) |
| KR (3) | KR20220028125A (pt) |
| CN (3) | CN111920939A (pt) |
| AU (2) | AU2014364528C1 (pt) |
| BR (1) | BR112016013961A2 (pt) |
| CA (1) | CA2933601A1 (pt) |
| CY (1) | CY1122604T1 (pt) |
| DK (1) | DK2986308T3 (pt) |
| EA (1) | EA037823B1 (pt) |
| ES (1) | ES2771749T3 (pt) |
| HR (1) | HRP20200009T1 (pt) |
| HU (1) | HUE047062T2 (pt) |
| IL (1) | IL246162B (pt) |
| LT (1) | LT2986308T (pt) |
| MX (2) | MX2016008108A (pt) |
| NZ (1) | NZ721089A (pt) |
| PL (1) | PL2986308T3 (pt) |
| PT (1) | PT2986308T (pt) |
| RS (1) | RS59804B1 (pt) |
| SI (1) | SI2986308T1 (pt) |
| WO (1) | WO2015095535A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| NZ721089A (en) | 2013-12-18 | 2022-10-28 | The George Washington Univ A Congressional Chartered Not For Profit Corporation | Angiotensin ii alone or in combination for the treatment of hypotension |
| TW202214219A (zh) * | 2014-07-08 | 2022-04-16 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| WO2016153558A1 (en) | 2015-03-20 | 2016-09-29 | Atkinson Arthur J | Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| JP2019501201A (ja) * | 2016-01-07 | 2019-01-17 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | アンジオテンシンｉｉの投与方法 |
| BR112018013852A2 (pt) * | 2016-01-07 | 2018-12-18 | La Jolla Pharmaceutical Company | métodos de administração de vasopressores |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| WO2019118874A1 (en) * | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
| WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| WO2002098906A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| WO2005044313A2 (en) | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
| FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
| CN101316626A (zh) | 2005-09-29 | 2008-12-03 | 菲布罗根公司 | 用于降低血压的方法 |
| CN101351215A (zh) * | 2005-12-30 | 2009-01-21 | 霍华德·弗洛里实验生理学及医学研究所 | 治疗方法 |
| US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| AU2007321111A1 (en) | 2006-11-17 | 2008-05-22 | Da Volterra | Colonic delivery using Zn/pectin beads with a Eudragit coating. |
| WO2009009907A1 (en) | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| JP2012510468A (ja) | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| JP2013532635A (ja) | 2010-07-14 | 2013-08-19 | カンバーランド エマージング テクノロジーズ，インコーポレーテッド | トロンボキサン−ａ２受容体アンタゴニストでの肝腎症候群および肝性脳症の治療方法 |
| CN105592855A (zh) | 2013-04-26 | 2016-05-18 | 拉卓拉药物公司 | 用于治疗肾衰竭的组合物和方法 |
| NZ721089A (en) | 2013-12-18 | 2022-10-28 | The George Washington Univ A Congressional Chartered Not For Profit Corporation | Angiotensin ii alone or in combination for the treatment of hypotension |
| US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
| TW202214219A (zh) | 2014-07-08 | 2022-04-16 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| JP2019501201A (ja) | 2016-01-07 | 2019-01-17 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | アンジオテンシンｉｉの投与方法 |
| BR112018013852A2 (pt) | 2016-01-07 | 2018-12-18 | La Jolla Pharmaceutical Company | métodos de administração de vasopressores |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| WO2019118874A1 (en) | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
-
2014
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko active Application Filing
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active IP Right Grant
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en active Application Filing
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 EP EP19197866.7A patent/EP3607962A1/en active Pending
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 MX MX2016008108A patent/MX2016008108A/es unknown
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Application Discontinuation
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-03 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en active Pending
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja active Pending
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016013961A2 (pt) | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão | |
| BR112016002781A2 (pt) | métodos e dispositivos para puncionar tecido | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| PH12020500555A1 (en) | Esketamine for the treatment of depression | |
| BR112018016341A2 (pt) | solução de bloqueio do cateter e terapia de bloqueio do cateter | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| BR112015020918A2 (pt) | métodos para tratar o hcv | |
| BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| PH12015502655A1 (en) | Method | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| MX2022010093A (es) | Tafoxiparina para el tratamiento de la preeclampsia. | |
| BR112015026973A2 (pt) | uso de vanoxerina no tratamento de arritmia cardíaca | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| BR112015021363A2 (pt) | adrenérgico alfa-2 para tratamento pressão intraocular e doenças oculares através de vias intravítreas e intracamerais | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| BR112015028334A2 (pt) | agente e método para o tratamento de herpes | |
| MX2018005453A (es) | Uso terapeutico de una solucion oftalmica acuosa esteril. | |
| BR112017014467A2 (pt) | uso de uma mistura de polímeros modificados de glicose para reduzir a metástase tumoral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |